Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Identifieur interne : 001F66 ( PubMed/Checkpoint ); précédent : 001F65; suivant : 001F67Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Auteurs : Gerd R. Burmester [Allemagne] ; Andrea Rubbert-Roth [Allemagne] ; Alain Cantagrel [France] ; Stephen Hall [Australie] ; Piotr Leszczynski [Pologne] ; Daniel Feldman [Brésil] ; Madura J. Rangaraj [États-Unis] ; Georgia Roane [États-Unis] ; Charles Ludivico [États-Unis] ; Min Bao [États-Unis] ; Lucy Rowell [Royaume-Uni] ; Claire Davies [Royaume-Uni] ; Eduardo F. Mysler [Argentine]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2016.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Antirhumatismaux (administration et posologie), Antirhumatismaux (effets indésirables), Association de médicaments, Facteurs temps, Humains, Indice de gravité médicale, Injections sous-cutanées, Injections veineuses, Méthode en double aveugle, Polyarthrite rhumatoïde (traitement médicamenteux), Résultat thérapeutique, Voies d'administration de substances chimiques et des médicaments.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Antirhumatismaux.
- effets indésirables : Anticorps monoclonaux humanisés, Antirhumatismaux.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- Association de médicaments, Facteurs temps, Humains, Indice de gravité médicale, Injections sous-cutanées, Injections veineuses, Méthode en double aveugle, Résultat thérapeutique, Voies d'administration de substances chimiques et des médicaments.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (adverse effects), Arthritis, Rheumatoid (drug therapy), Double-Blind Method, Drug Administration Routes, Drug Therapy, Combination, Humans, Injections, Intravenous, Injections, Subcutaneous, Severity of Illness Index, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- drug therapy : Arthritis, Rheumatoid.
- Double-Blind Method, Drug Administration Routes, Drug Therapy, Combination, Humans, Injections, Intravenous, Injections, Subcutaneous, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) and inadequate response to disease-modifying antirheumatic drugs (DMARDs).
DOI: 10.1136/annrheumdis-2015-207281
PubMed: 26056119
Affiliations:
- Allemagne, Argentine, Australie, Brésil, France, Pologne, Royaume-Uni, États-Unis
- Berlin, Californie, Caroline du Sud, District de Cologne, Louisiane, Midi-Pyrénées, Occitanie (région administrative), Pennsylvanie, Rhénanie-du-Nord-Westphalie, État de São Paulo
- Berlin, Cologne, São Paulo, Toulouse
- Université de Cologne
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26056119Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Free University and Humboldt University of Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Free University and Humboldt University of Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="4"><nlm:affiliation>Klinikum der Universität zu Köln, Köln, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinikum der Universität zu Köln, Köln</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Cologne</settlement><settlement type="city">Cologne</settlement></placeName><orgName type="university">Université de Cologne</orgName></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:affiliation>Cabrini Medical Centre, Malvern, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Medical Centre, Malvern</wicri:regionArea><wicri:noRegion>Malvern</wicri:noRegion></affiliation></author><author><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name><affiliation wicri:level="1"><nlm:affiliation>Poznan Medical University, Poznan, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Poznan Medical University, Poznan</wicri:regionArea><wicri:noRegion>Poznan</wicri:noRegion></affiliation></author><author><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name><affiliation wicri:level="3"><nlm:affiliation>Universidade Federal de São Paulo, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal de São Paulo, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name><affiliation wicri:level="2"><nlm:affiliation>Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana</wicri:regionArea><placeName><region type="state">Louisiane</region></placeName></affiliation></author><author><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name><affiliation wicri:level="2"><nlm:affiliation>Rheumatology Associates of South Carolina, Charleston, South Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rheumatology Associates of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><affiliation wicri:level="2"><nlm:affiliation>East Penn Rheumatology Associates, Bethlehem, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>East Penn Rheumatology Associates, Bethlehem, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Limited, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Limited, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Davies, Claire" sort="Davies, Claire" uniqKey="Davies C" first="Claire" last="Davies">Claire Davies</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Limited, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Limited, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name><affiliation wicri:level="1"><nlm:affiliation>Organizacion Medica de Investigación, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Organizacion Medica de Investigación, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26056119</idno><idno type="pmid">26056119</idno><idno type="doi">10.1136/annrheumdis-2015-207281</idno><idno type="wicri:Area/PubMed/Corpus">002441</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002441</idno><idno type="wicri:Area/PubMed/Curation">002395</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002395</idno><idno type="wicri:Area/PubMed/Checkpoint">002395</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002395</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Free University and Humboldt University of Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Free University and Humboldt University of Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="4"><nlm:affiliation>Klinikum der Universität zu Köln, Köln, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinikum der Universität zu Köln, Köln</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Cologne</settlement><settlement type="city">Cologne</settlement></placeName><orgName type="university">Université de Cologne</orgName></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:affiliation>Cabrini Medical Centre, Malvern, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Medical Centre, Malvern</wicri:regionArea><wicri:noRegion>Malvern</wicri:noRegion></affiliation></author><author><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name><affiliation wicri:level="1"><nlm:affiliation>Poznan Medical University, Poznan, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Poznan Medical University, Poznan</wicri:regionArea><wicri:noRegion>Poznan</wicri:noRegion></affiliation></author><author><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name><affiliation wicri:level="3"><nlm:affiliation>Universidade Federal de São Paulo, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal de São Paulo, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name><affiliation wicri:level="2"><nlm:affiliation>Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana</wicri:regionArea><placeName><region type="state">Louisiane</region></placeName></affiliation></author><author><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name><affiliation wicri:level="2"><nlm:affiliation>Rheumatology Associates of South Carolina, Charleston, South Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rheumatology Associates of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><affiliation wicri:level="2"><nlm:affiliation>East Penn Rheumatology Associates, Bethlehem, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>East Penn Rheumatology Associates, Bethlehem, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="2"><nlm:affiliation>Genentech Inc, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech Inc, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Limited, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Limited, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Davies, Claire" sort="Davies, Claire" uniqKey="Davies C" first="Claire" last="Davies">Claire Davies</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Limited, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Limited, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name><affiliation wicri:level="1"><nlm:affiliation>Organizacion Medica de Investigación, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Organizacion Medica de Investigación, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (adverse effects)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Double-Blind Method</term><term>Drug Administration Routes</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Injections, Intravenous</term><term>Injections, Subcutaneous</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (effets indésirables)</term><term>Association de médicaments</term><term>Facteurs temps</term><term>Humains</term><term>Indice de gravité médicale</term><term>Injections sous-cutanées</term><term>Injections veineuses</term><term>Méthode en double aveugle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Voies d'administration de substances chimiques et des médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Drug Administration Routes</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Injections, Intravenous</term><term>Injections, Subcutaneous</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Facteurs temps</term><term>Humains</term><term>Indice de gravité médicale</term><term>Injections sous-cutanées</term><term>Injections veineuses</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Voies d'administration de substances chimiques et des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) and inadequate response to disease-modifying antirheumatic drugs (DMARDs).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26056119</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>15</Day></DateCreated><DateCompleted><Year>2016</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).</ArticleTitle><Pagination><MedlinePgn>68-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2015-207281</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) and inadequate response to disease-modifying antirheumatic drugs (DMARDs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients (n=1262) were randomised 1:1 to receive TCZ-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or TCZ-IV 8 mg/kg q4w+placebo-SC qw in combination with DMARD(s). After a 24-week double-blind period, patients receiving TCZ-SC were re-randomised 11:1 to TCZ-SC (n=521) or TCZ-IV (TCZ-SC-IV, n=48), and patients receiving TCZ-IV were re-randomised 2:1 to TCZ-IV (n=372) or TCZ-SC (TCZ-IV-SC; n=186). Maintenance of clinical responses and safety through week 97 were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The proportions of patients who achieved American College of Rheumatology (ACR)20/50/70 responses, Disease Activity Score in 28 joints remission and improvement from baseline in Health Assessment Questionnaire Disability Index ≥0.3 were sustained through week 97 and comparable across arms. TCZ-SC had a comparable safety profile to TCZ-IV through week 97, except that injection site reactions (ISRs) were more common with TCZ-SC. Safety profiles in patients who switched were similar to those in patients who received continuous TCZ-SC or TCZ-IV treatment. The proportion of patients who developed anti-TCZ antibodies remained low across treatment arms. No association between anti-TCZ antibody development and clinical response or adverse events was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The long-term efficacy and safety of TCZ-SC was maintained and comparable to that of TCZ-IV, except for ISRs. Profiles in patients who switched formulations were comparable to those in patients who received TCZ-IV or TCZ-SC. TCZ-SC provides additional treatment options for patients with RA.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT01194414.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burmester</LastName><ForeName>Gerd R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Free University and Humboldt University of Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubbert-Roth</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinikum der Universität zu Köln, Köln, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantagrel</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cabrini Medical Centre, Malvern, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leszczynski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Poznan Medical University, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidade Federal de São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangaraj</LastName><ForeName>Madura J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Arthritis & Diabetes Clinic, Inc, Monroe, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roane</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Rheumatology Associates of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludivico</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>East Penn Rheumatology Associates, Bethlehem, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech Inc, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowell</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Roche Products Limited, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Roche Products Limited, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mysler</LastName><ForeName>Eduardo F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Organizacion Medica de Investigación, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01194414</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2008 Oct;58(10):2968-80</RefSource><PMID Version="1">18821691</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Care Res (Hoboken). 2014 Nov;66(11):1653-61</RefSource><PMID Version="1">24942540</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2014 Jan;73(1):69-74</RefSource><PMID Version="1">23904473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54</RefSource><PMID Version="1">23983039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2008 Mar 22;371(9617):987-97</RefSource><PMID Version="1">18358926</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 May 4;381(9877):1541-50</RefSource><PMID Version="1">23515142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Prefer Adherence. 2014 Jan 20;8:93-9</RefSource><PMID Version="1">24470758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2008 Nov;67(11):1516-23</RefSource><PMID Version="1">18625622</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Rheum Dis. 2010 Jan;69(1):88-96</RefSource><PMID Version="1">19297346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Prefer Adherence. 2014 Aug 01;8:1051-9</RefSource><PMID Version="1">25120354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2011 Mar;63(3):609-21</RefSource><PMID Version="1">21360490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Prefer Adherence. 2009 Nov 29;3:335-44</RefSource><PMID Version="1">20016797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S14-8</RefSource><PMID Version="1">22073935</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004333" MajorTopicYN="N">Drug Administration Routes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4717437</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DMARDs (biologic)</Keyword><Keyword MajorTopicYN="N">Rheumatoid Arthritis</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26056119</ArticleId><ArticleId IdType="pii">annrheumdis-2015-207281</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2015-207281</ArticleId><ArticleId IdType="pmc">PMC4717437</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Australie</li><li>Brésil</li><li>France</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Berlin</li><li>Californie</li><li>Caroline du Sud</li><li>District de Cologne</li><li>Louisiane</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Pennsylvanie</li><li>Rhénanie-du-Nord-Westphalie</li><li>État de São Paulo</li></region><settlement><li>Berlin</li><li>Cologne</li><li>São Paulo</li><li>Toulouse</li></settlement><orgName><li>Université de Cologne</li></orgName></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name></region><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name></region></country><country name="Australie"><noRegion><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name></noRegion></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name></region></country><country name="États-Unis"><region name="Louisiane"><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name></region><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name></noRegion><name sortKey="Davies, Claire" sort="Davies, Claire" uniqKey="Davies C" first="Claire" last="Davies">Claire Davies</name></country><country name="Argentine"><noRegion><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001F66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26056119
|texte= Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26056119" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |